Navigation Links
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Date:3/2/2010

he vaccine's efficacy are expected.

In December 2009, the interim analysis from 225 patients has shown good safety, tolerability and immunogenicity of the vaccine, with final data expected in Q3 2010.

Additional candidate vaccines with high medical need progressing in development

Streptococcus pneumoniae vaccine: Results were reported in February 2010 from a first Phase I clinical trial of the Company's investigational prophylactic Streptococcus pneumoniae vaccine candidate. Intercell's Streptococcus pneumoniae vaccine candidate demonstrated a good safety and tolerability profile in all study groups. In addition, the vaccine was shown to be immunogenic, and antigen dose-dependent induction of antibodies was confirmed for all three proteins of the vaccine.

The development of Intercell's Streptococcus pneumoniae vaccine is supported by PATH (Program for Appropriate Technology in Health), a U.S.-based non-profit organization dedicated to finding solutions for global health.


'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
2. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
3. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. Iomai Stockholders Approve Merger With Intercell Subsidiary
6. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
7. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2
... (OTC Bulletin Board: CHBT), a leading Chinese firm ... of,probiotics dietary supplements, today announced it will host ... August 15, 2008, to discuss the Company,s,financial results ... of its fiscal,2009., Hosting the call will ...
... Aug. 7 Campbell Alliance, the leading,management consulting ... announced that Nader Naeymi-Rad has been appointed Chief,Operating ... Senior Vice,President and head of the firm,s Brand ... the same title., This new senior executive ...
... be Marketed Worldwide, ALEXANDRIA, Va. and ... (SAFRAN Group) the industry leader in multi-biometric,solutions, ... BKYI), a,leader in finger-based biometric identification and ... partnership that combines the,strengths of both companies ...
Cached Biology Technology:China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 2China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 3Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 2Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance 3Sagem Morpho and BIO-key Announce Biometric Partnership Agreement 2Sagem Morpho and BIO-key Announce Biometric Partnership Agreement 3
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this market ... systems utilize more than one characteristic of an individual ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... (New York City, October 20, 2011) In the October 20th ... Drs. Claudia Plottel and Martin J. Blaser of the Departments ... the Department of Biology at New York University, present a ... an understanding of the bacteria living in our body, the ...
... Inc., a company using its proprietary Protein Design ... announced today the initiation of a Phase 1 ... for the treatment of autoimmune diseases. XmAb5871 uses ... disorders that may avoid some of the side ...
... have found that pressure from increasing coastal populations, ship ... are critically threatening the health of the Florida Keys ... sea turtles and coral habitat continue to be at ... findings were released today in the Condition Report 2011 ...
Cached Biology News:Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases 2NOAA releases status on Florida Keys National Marine Sanctuary marine resources 2
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... TAMRA isomers are predominantly used for labeling ... for labeling peptides and nucleotides because they ... is often required in the conjugation processes. ... for labeling peptides and proteins. 6-TAMRA is ...
anti-Lactate Dehydrogenase...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: